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Abstract
Increased activity of lung epithelial sodium channels (ENaCs)
contributes to the pathophysiology of cystic fibrosis (CF) by
increasing the rate of epithelial lining fluid reabsorption. Inter-
a-inhibitor (IaI), a serum protease inhibitor, may decrease ENaC
activity by preventing its cleavage by serine proteases. High
concentrations of IaI were detected in the bronchoalveolar lavage
fluid (BALF) of children with CF and lower airway diseases. IaI
decreased amiloride-sensitive (IENaC) but not cAMP-activated Cl
2
currents across confluent monolayers of rat ATII, and mouse nasal
epithelial cells grew in primary culture by 45 and 25%, respectively.
Changes in IENaC by IaI in ATII cells were accompanied by increased
levels of uncleaved (immature) surfacea-ENaC. IaI increased airway
surface liquid depth overlying murine nasal epithelial cells to the
same extent as amiloride, consistent with ENaC inhibition.
Incubation of lung slices from C57BL/6, those lacking phenylalanine
at position 508 (ΔF508), or CF transmembrane conductance
regulator knockout mice with IaI for 3 hours decreased the open
probability of their ENaC channels by 50%. ΔF508 mice had
considerably higher levels the amiloride-sensitive fractions of ENaC
nasal potential difference (ENaC-NPD) than wild-type littermates
and only background levels of IaI in their BALF. A single intranasal
instillation of IaI decreased their ENaC-NPD 24 hours later by
25%. In conclusion, we show that IaI is present in the BALF of
children with CF, is an effective inhibitor of ENaC proteolysis, and
decreases ENaC activity in lung epithelial cells of ΔF508 mice.
Keywords: alveolar type II cells; lung slices; human BAL;
cystic fibrosis; biotinylation
Epithelial sodium (Na1) channels (ENaCs)
are present at the apical membranes of
epithelial cells and play a major role in the
regulation of water movement, plasma
osmolality, blood pressure, and Na1
homeostasis (1, 2). In the lung, ENaCs play
an important role in maintaining the
composition and the thickness of the airway
surface liquid (3). ENaCs are formed by the
assembly of at least three subunits, a, b, and
g (2), although lung epithelial cells are
known to contain dENaCs as well (4).
Because of its critical role, ENaC activity is
tightly regulated at many levels (gene
expression, synthesis, assembly, degradation,
and trafficking to and from the plasma
membrane) by complex mechanisms. At the
plasma membrane, ENaC function is
controlled by a finely tuned equilibrium
between proteolytic activation (5, 6) and
ubiquitination/internalization followed by
degradation (7–9). Two membrane pools of
ENaCs are known to be present in epithelial
surfaces: an active, cleaved type, which
transports Na1, and an uncleaved type,
which does not transport Na1 but acts as
a depot for the active ENaC.
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Inter-a-inhibitor (IaI) is a serum
protease inhibitor consisting of three
polypeptides (10, 11). The two heavy chains
of the IaI molecule (which can be H1, H2,
or H3), sized between 75 and 90 kD, have
similar primary structures. The third so-
called light chain, also known as bikunin, is
of smaller size and molecular weight (25
kD) and confers the protease inhibitory
properties. The three polypeptides are
covalently linked by ester bonds to
a chondroitin sulfate backbone chain (11).
This complex, with a molecular weight of
225 kD, is produced by hepatocytes and
released into the blood stream, where it
reaches concentrations as high as 0.5 mg/ml
(12, 13). IaI covalently binds the
glycosaminoglycan hyaluronan (HA) (14),
and in the lung its presence is necessary for
HA-mediated airway hyperresponsiveness
after exposure to oxidants such as ozone
(15). However, IaI is also present in the
bronchoalveolar lavage fluid (BALF) after
lung injury (16). Thus, its presence could
confer benefit to patients with cystic fibrosis
(CF) by inhibiting ENaC activity and
consequently the Na1 hyperabsorption
associated with a lack of functional CF
transmembrane conductance regulator
(CFTR) (17).
We designed a series of experiments to
show the presence of IaI in BALF of children
with CF. Subsequently, we measured the
extent of IaI inhibition of amiloride-sensitive
currents across Xenopus oocytes expressing
human ENaCs and confluent monolayers
of rodent ATII and nasal epithelial cells.
We then incubated thinly cut lung slices
from C57BL/6 mice and those lacking
phenylalanine at position 508 (ΔF508) with
IaI and measured single-channel activity in
ATII cells in situ. Finally, because of our
previous studies demonstrating increased
ENaC activity in ΔF508 mice (17), we
instilled IaI intranasally in ΔF508 mice
and measured the amiloride-sensitive
components of nasal potential difference
(ENaC-NPD) as an index of Na1 transport
across the nasal airway epithelium. Taken
together, our findings suggest that IaI plays
a protective role by limiting the degree of
Na1 hyperabsorption in wild-type and
murine models of CF.
Materials and Methods




BALF was obtained from children undergoing
clinically indicated bronchoscopy at the
Children’s Hospital at the University of
North Carolina, Chapel Hill, North Carolina.
The Institutional Review Board approved
collection of excess BALF. All parents signed
consent, and assent was obtained in children
old enough to read.
Animals
Cftr knockout mice (B6.129P2-Cftrtm1Unc/J;
Cftr(2/2)) (18) and Cftr-ΔF508 mice
(B6.129S6-Cftrtm1Kth/J; ΔF508) (19)
backcrossed extensively to C57BL/6 mice to
make them congenic were provided by the
University of Alabama at Birmingham
Cystic Fibrosis Center Mouse Genetics
Core Facility. All procedures involving
animals were approved by the University of
Alabama at Birmingham Institutional
Animal Care and Use Committee.
Measurement of IaI and HA
Concentrations in Human BALF
IaI in BALF were determined using
a competitive ELISA as previously
described (20). HA concentrations were
determined using a competitive ELISA
(Echelon, San Jose, CA).
Recording of Single-Channel
Currents from ATII Cells in
Lung Slices
ATII cells in lung slices were patched in the
cell-attached mode, and Na1 single-channel
activity was recorded after incubation of
slices with vehicle or IaI (0.1 mg/ml) for
3 hours as previously described (17, 21).
Short-Circuit Currents across
ATII Cells
Confluent monolayers of rat ATII cells (17)
or murine (C57BL/6) nasal epithelial cells
(22) were incubated with IaI (0.1 mg/ml) in
100 ml of Normal Ringers added on their
apical side for 2 or 4 hours. Cells were
mounted in Ussing chambers, and short-
circuit currents (Isc) and transepithelial
resistances were measured before and after
addition of amiloride (10 mM), forskolin
(10 mM), and glibenclamide (400 mM) in
the apical compartments (21, 23, 24).
Surface Biotinylation and
Western Blotting
Rat ATII cells were treated with IaI
(100 mg/ml) or vehicle for 4 hours. They were
rinsed with cold PBS and incubated with 1
mg/ml of EZ-Link Sulfo-NHS-SS-biotin
(Pierce) in PBS (pH 8.0) for 30 minutes
(25). The biotinylation reaction was
quenched with 50 mM TRIS for 5 minutes,
and the cells were washed again with PBS
and lysed in RIPA buffer containing
protease inhibitor cocktail (Roche). One
milligram of lysate was incubated with
50 ml of packed streptavidin–agarose
(Novagen) overnight at 48C. After
incubation, the streptavidin–agarose beads
were extensively washed with lysis buffer.
Bound proteins were eluted with Laemmle
23 sample buffer and separated by 10%
SDS-PAGE gels (Bio-Rad). Proteins were
then transferred to polyvinylidene fluoride
membranes and immunoblotted with an
antibody against a-ENaCs (Thermo
Scientific, Rockford, IL). Proteins were
visualized using chemiluminescence.
Specific binding was assessed by
immunostaining with the antibody against
a-ENaCs in the presence of the
immunizing peptide (21).
NPD
NPDs were measured following the method
of Knowles and colleagues (26) and as
previously described (24) 4 or 24 hours
after intranasal instillation of 25 ml of
lactated Ringer’s solution with IaI (100 mg/ml)
or alone in each nostril.
Statistics
One-way ANOVA and the Bonferroni t test,
adjusted for multiple comparisons, were
used to determine differences among group
means. Differences at P , 0.05 were
considered significant.
Results
IaI and HA Concentrations Increased
in BALF of Pediatric Patients with
CF and in Patients with Pneumonia
BALF from 36 children with CF and 17
children with lower airway diseases
(recurrent pneumonia, asthma, cough, and
two patients with primary ciliary dyskinesia)
were included. Indications for
bronchoscopy in CF were mainly for
exacerbations failing oral or intravenous
antibiotics in nonexpectorating children,
new detection of Pseudomonas aeruginosa
infection (n = 6), and surveillance
bronchoscopy at the time of another
surgery (n = 3). As such, a majority of
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subjects were on antibiotics before
bronchoscopy, but these were held at least
48 hours prior to the procedure in all
but two subjects. Further clinical and
BALF data are shown in Table E1 in the
online supplement. The percentage of
polymorphonuclear leukocytes in BALF
was significantly higher in patients with
CF versus patients without CF (67 6 3.6 vs.
34 6 8.1; X 6 1 SE; P = 0.002 with Mann-
Whitney test; n = 36 and 17, respectively)
Because IaI accumulates in sites of
inflammation (27), we investigated whether
IaI concentrations were increased in the
BALF of these patients. IaI values in
patients with CF (41 6 4.2 mg/ml; n = 36)
were significantly higher than in patients
withut CF (11.3 6 51 mg/ml [n = 17
samples]; X 6 1 SE; P , 0.0001; Mann
Whitney test) (Figure 1A). There was
a linear correlation between IaI and
number of inflammatory cells in the BALF
(R2 = 0.49) for patients with CF
(Figure 1B). Patients with CF also had
significantly higher levels of HA in their
BALF as compared with those without CF
(15.6 6 1.7 [n = 36 samples] vs. 4.1 6 2.3
[n = 17 samples]; X 6 1 SEM;P = 0.0002
with Mann-Whitney test). There was
a significant correlation among IaI and HA
concentrations in the BALF (Figure 1C).
IaI Inhibits ENaCs Heterologously
Expressed in Xenopus Oocytes
Perfusion of Xenopus oocytes expressing
human a-, b-, and g-ENaCs with ND96
containing 0.1 mg/ml IaI under voltage
clamp conditions led to a time-dependent
inhibition of whole-cell Na1 current (INa)
(Figure 2A). The mean rate constant (t) of
decay, calculated by fitting the INa with
a mono-exponential decay equation [y =
A 3 e(2INa/t) 1 B] (28), was 18.0 6 0.85
minutes (X 6 SEM; n = 17). Addition of
trypsin (2 mM) in the perfusion medium
reversed the inhibitory effects of IaI on INa
by most likely activating silent Na1
channels at their plasma membranes
(Figure 2A). Subsequently, oocytes
were incubated with IaI (0.1 mg/ml) or
medium (ND96) for 60 minutes, and
current–voltage (I–V) relationships were
obtained in the absence and presence of
amiloride (10 mM) in the perfusion
medium. Amiloride-sensitive currents
(IENaC,; indicative of the component of Na
1
currents due to ENaC) (Figure 2B)
exhibited inwardly rectified currents, which
were inhibited largely by IaI. On the other
hand, IaI did not alter the reversal
potential, suggesting that the ENaC
permeability ratio of Na1/K1 was not
affected. No change of IENaC currents was
seen when ENaC-expressing oocytes were
incubated with IaI and an antibody against
IaI for 60 minutes (Figure 2C).
Figure 1. Children with cystic fibrosis (CF) have increased concentrations of inter-a-inhibitor (IaI) in their bronchoalveolar lavage fluid (BALF). (A) Samples
were stratified according to the primary diagnosis (CF = cystic fibrosis; Non-CF = lower airway disease). IaI was measured in the cell-free lavage as
described in MATERIALS AND METHODS. Box whisker plots showing individual data points, boxes, whiskers (2 SD from the mean), means, and standard errors
(*P = 0.0.0026 with Mann-Whitney test; n = 16 for Non-CF and n = 36 for CF). (B) IaI concentrations versus log10 (number of inflammatory cells) in
the BALF for patients with CF and non-CF subjects. The straight line represents best line of fit for the CF samples (IaI = 30.43 3 log (cells) of cells 2150;
R = 0.7; P , 0.001). (C) Hyaluronan (HA) versus IaI in the BALF. The straight line represents best line of fit for all patients (R2 = 0.6; P , 0.05).
ORIGINAL RESEARCH
Lazrak, Jurkuvenaite, Ness, et al.: IaI Inhibits Na1 Transport in ΔF508 Mice 955
IaI Inhibits Na1 but Not Cl2 Currents
across Rat ATII Monolayers
To test the effects of IaI on native ENaC,
IaI (0.1 mg/ml) or vehicle were added to
the apical surfaces of confluent monolayers
of rat ATII cells (21, 29) for 2 or 4 hours.
ATII cells were then mounted in Ussing
chambers, and Isc was recorded
continuously (Figures 3A and 3B). No
changes were seen at 2 hours after IaI
addition. However, IaI decreased the
amiloride-sensitive component of Isc
(IENaC) at 4 hours after incubation from
4.3 6 0.4 mA to 2.34 6 0.25 mA (X 6 1
SEM; vehicle = 19; IaI = 21; **P , 0.01).
The forskolin-activated and glibenclamide-
inhibited component of Isc (Figures 3A and
3B) and the transepithelial resistances
remained at baseline levels (data not
shown). Similarly, incubation of murine
nasal cells with IaI (0.1 mg) for 4 hours
decreased their IENaC from 3.8 6 0.23 to
3.0 6 0.08 (X 6 1 SEM; n = 6; P = 0.0023).
These data indicate that IaI decreased
native murine ENaCs and human ENaCs
expressed in Xenopus oocytes.
To obtain additional insight into the
mechanisms by which IaI decreased ENaC
activity, we isolated total and surface
proteins from ATII cells incubated with IaI
for 4 hours and immunostained them using
an a-ENaC antibody. Bands around 95 kD,
indicative of uncleaved aENaCs, were seen
in total and surface proteins (Figure 4).
These bands increased significantly after
incubation of ATII cells with IaI for
4 hours. The specificity of the anti–a-ENaC
antibody was verified by the disappearance
of these bands when Western blotting
studies were repeated in the presence of the
immunizing peptide. In previous studies we
have shown that a-antitrypsin decreased
the 65 kD band in Xenopus oocytes injected
with human a-, b-, and g-ENaCs (28).
Planes and colleagues (30) detected a 65-kD
band in surface but not total proteins from
ATII cells, which they attributed to
cleaved aENaCs. However, these authors
were unable to detect the high-molecular
Figure 2. IaI inhibits human epithelial sodium channel (ENaC) expressed in Xenopus oocytes. (A) Time
course of inward Na1 currents (INa
1) across Xenopus oocytes injected with cRNAs encoding wild-type
a-, b-, and g- human-ENaC (8.4 ng each). Addition of amiloride (10 mM) in the perfusion medium
decreased INa
1 from 240 to 25 mA. Perfusion with amiloride-free medium (ND96) restored INa
1 to
240 mA. Perfusion with ND96 containing IaI (0.1 mg/ml) resulted in a time-dependent decrease of INa
1.
Addition of trypsin (2 mM) restored INa
1 to its initial value. Results are from a typical experiment, which
was repeated at least five times. (B) Oocytes were incubated with 0.1 mg/ml IaI or vehicle (ND96) for
60 minutes. Current voltage curves for amiloride-sensitive currents (IENaC) were calculated as described in
MATERIALS AND METHODS. Values are means 6 SE; n (number of oocytes from 3 or 4 experiments) = 21 for
vehicle and 19 for IaI. (C) ENaC-expressing oocytes were incubated with vehicle (ND96) or with equal
concentrations of IaI and a specific blocking antibody (mAB) against IaI (0.1 mg/ml). Values means6 SE;
n (number of oocytes from three or four experiments) = 8 for vehicle and 7 for IaI1mAB. Veh, vehicle.
Figure 3. IaI inhibits ENaC but not CF transmembrane conductance regulator (CFTR) short-circuit current (Isc) across ATII cell monolayers. (A) ATII cell
monolayers were incubated with IaI (0.1 mg/ml added to their apical surface) for 2 or 4 hours at 378C and mounted in Ussing chambers for the
measurement of Isc. Amiloride (A; 10 mM), forskolin (F; 10 mM), and glibenclamide (G; 400 mM) were added sequentially in the apical chambers. (A, B)
Typical experiments after incubation of ATII cell monolayers with IaI for 2 or 4 hours.
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weight-bands as we did in our experiments.
Differences in culture conditions and protein
loading and the use of antibodies from different
sources may account for these differences.
IaI Inhibits ENaCs In Situ
To more definitively document the effects of
IaI on ATII cell ENaCs, we incubated
freshly prepared lung slices from C57BL/6
mice with IaI (0.1 mg/ml) for 4 hours,
patched ATII cells in situ using the
cell-attached mode of patch clamp
configuration, and recorded ENaC activity
in situ as reported earlier (17, 21). Two
distinct Na1 channels with conductances of
4 and 18 pS were observed (Figure 5A).
Both channels were inhibited by amiloride
(21). The 4-pS channel is thought to
represent ENaCs, whereas the 18-pS
channel is a cation channel with equal
permeability to Na1 and K1 ions.
Incubation of lung slices with IaI inhibited
the activity of both channels (Figures 5B
and 5C) and decreased their open
probabilities (Po) (Figures 5D and 5E). This
effect was abolished when lung slices were
incubated simultaneously with IaI and an
antibody against IaI (Figures 5D and 5E).
IaI Partially Reverses Increased ENaC
Activity in ATII Cells from CFTR2/2
and ΔF-508 ATII Mice
ΔF-508 and CFTR2/2 mice have higher
levels of lung ENaC activity (17, 31) but
only background levels of IaI in their BALS
(ΔF-508: 0.1 6 0.02 [n = 8 mice]; C57BL/6:
0.075 6 0.045 [n = 7 mice]; X 6 SEM;
P = 0.66). We questioned whether
incubation of lung slices from ΔF-508 and
CFTR2/2 mice with IaI would reduce
ENaC activity. The results of these studies
are shown in Figure 6. As reported
previously (17), ATII cells from ΔF-508 and
CFTR(2/2) mice exhibited significantly
higher Po values for the 4-pS (Figure 6)
and the 18-pS channels (Figure E1).
Incubation of slices with 0.1 mg/ml IaI for
4 hours reduced Po values of both channels
close to normal levels.
IaI Increased the Airway Surface
Liquid Depth Overlying Primary
Murine Nasal Epithelial Cells
The volume of fluid on apical surface of
murine nasal epithelial cells depends on the
balance between Na1 reabsorption (mainly
through ENaCs) and Cl2 secretion (mainly
through CFTR) (22). Addition of IaI
(0.1 mg) to the apical surface of confluent
monolayers of primary murine nasal
epithelial cells increased the airway surface
liquid depth to the same extent as amiloride
(vehicle, 5.6 6 0.1 [n = 11]; IaI, 7.2 6
0.3 [n = 11]; amiloride, 8 6 0.44 [n = 14])
(Figures 6B and 6C). These data indicated
that IaI decreased ENaCs but not CFTR
(or at least it decreased ENaCs to a much
higher extent than CFTR), in agreement
with our Isc measurements across ATII cell
monolayers (Figure 3).
IaI Reduces Amiloride-Sensitive NPD
Values of ΔF-508 Mice
NPD values are dependent on the rate of
Na1 absorption and Cl2 secretion by nasal
epithelial cells. The amiloride-sensitive
NPD (ENaC-NPD) values in wild-type
and ΔF508 mice were 26.95 6 0.37 mV
(mean 6 SE; n = 10) and 223 6 0.31 mV
(mean 6 SE; n = 20), respectively. Four
hours after intranasal instillation of IaI, the
absolute values of these variables were
reduced by 23% (Figure 6D). The
magnitude of this decrease is similar to the
decrease of the amiloride-sensitive Isc
across nasal epithelial cells in primary
culture. This effect was still present at
24 hours after instillation.
Discussion
The mechanisms involved in the activation
and removal of ENaCs from the plasma
membranes of epithelial cells are not well
understood. Activation involves membrane-
bound proteases, such as furin, prostasin,
and matriptase, which activate ENaCs by
cleaving critical amino acids in a- and
g-ENaC subunits or by activating signaling
pathways (6, 32–35). Kunitz-type protease
inhibitors, such as aprotinin, inactivate
serine proteases, including trypsin, plasmin,
and kallikreins (36); a1-antitrypsin, an
acute phase glycoprotein and a member of
the SERPIN (serine protease inhibitors)
superfamily (37), also inhibit ENaC activity
(6, 28, 38). Herein, we demonstrate for the
first time that IaI, a plasma protein that is
also expressed by airway epithelia, is
present in the BALF of children with CF
and lower airway disease. In addition, our
data show that IaI inhibits ENaC activity
across Xenopus oocytes expressing human
ENaCs, decreases amiloride-sensitive
currents across confluent monolayers of rat
Figure 4. IaI increase uncleaved ENaC. Western blots of total and surface proteins from rat ATII cells
with an antibody against a-ENaC in the absence and presence of the immunizing peptide are shown.
ATII cells were isolated from rat lungs, seeded on permeable supports, and cultured under
liquid–liquid (3 d) and air–liquid (1–2 d) interfaces. IaI (0.1 mg/ml) was added on their apical surface.
Four hours later, cells were lysed, and total and surface (biotinylated) proteins were isolated.
Representative total (all proteins except those in the apical plasma membranes) and surface
(biotinylated; proteins in apical surface) aENaC Western blots in the absence and presence of the
immunizing peptide are shown. For surface labeling, 250 mg of protein were loaded with neutravidin
beads as described in MATERIALS AND METHODS. A total of 40 mg of protein were used. This experiment was
repeated three times with similar results. Equal amounts of protein were loaded in each lane as verified
by amido-black staining at the end of each experiment (data not shown). Notice the disappearance of
all bands in the surface pool in the absence of biotin. The specificity of the anti-aENaC antibody was
verified by the absence of staining in the presence of the immunizing peptide. IaI increased the intensity of
the 95-kD band (uncleaved ENaC) in total and surface proteins. MW, molecular weight.
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ATII and mouse nasal epithelial cells, and
decreases the open probabilities of two
different types of ATII cell amiloride-
sensitive currents in situ. In agreement with
our previous findings (17), data shown here
indicate that ATII cells from ΔF508 and
CFTR(2/2) mice have higher ENaC activity
than wild-type mice. Furthermore, ΔF508
mice showed more negative amiloride-
sensitive NPDs, consistent with higher
ENaC activity in the lungs of these mice.
Intranasal instillation of IaI decreased
ENaC-NPD by 25%, and this effect
persisted for up to 24 hours after
instillation. Western blotting studies in
surface proteins of ATII cells show that IaI
increases uncleaved (inactive) aENaCs,
thus providing insight into the mechanisms
involved. Our findings contribute to the
understanding of the role played by ENaCs
in lung fluid regulation in health and
disease and suggest that IaI contributes to
the homeostatic regulation of ENaCs in
wild-type mice and in those with the most
common CFTR mutation and in mice
lacking the CFTR genes.
IaI consists of two heavy chains and
a light chain, bikunin (39), which is
responsible for its antiprotease activity. IaI
is a fairly weak and nonspecific protease
inhibitor and makes up only approximately
5% of the total protease inhibitory activity
in plasma, even though it is present at a
fairly high concentrations (0.1–0.5 mg/ml)
(40). IaI is present in low concentrations in
the lung lining epithelial fluid of naive mice,
but its concentration increases significantly
when the epithelial permeability is
compromised, such as in lung injury or
inflammation. For example, we show that
IaI levels are very high in the BALF of
children with CF (Figure 1). There is a
linear correlation between the number of
inflammatory cells and levels of IaI in the
BALF of children with CF (Figure 1).
This suggests that IaI may be especially
up-regulated during inflammation. Our
current set of patients was not large enough
to stratify by other parameters (e.g., type of
infection). In previous studies, Garantziotis
and colleagues (27) showed colocalization
of IaI and HA in fibroblastic foci in
patients with interstitial pneumonitis. In
contrast to the human data, ΔF508 mice
(with no evidence of lung disease) have
normal levels of IaI in their BALF
(Figure 1).
Figure 5. IaI inhibits ENaC single-channel activity in AT2 cells in mouse lung slices. (A) Cell-attached patches of AT2 cells in lung slices at a holding
potential of 2100 mV . Note the presence of two Na1 channels with conductances of 4 and 18 pS. Both channels were totally inhibited by the addition of
amiloride (10 mM) in the pipette solution (data not shown; see Reference 21). Arrows indicate the simultaneous openings of the 4- and 18-pS channels.
(B) A similar record showing decreased channel activity after incubation of the slice with IaI (0.1 mg/ml) for 3 hours. (C) Histogram showing the
number of events versus current amplitude (pA) for the records shown in A and B. The corresponding conductances for the three peaks are 4 and 18 pS.
Typical records of experiments, which were repeated at least five times. (D, E) Mean values (6 1 SE) (n = 20 for each group) of the open probabilities (Po)
of the 4-pS (left panel) and 18-pS (right panel) Na1 channels obtained by patching ATII cells in lung slices incubated with medium (DMEM; Veh), IaI
(0.1 mg/ml), or IaI and an equal concentration of an antibody against IaI (mAB IaI; 0.1 mg/ml forz 3 h; *P, 0.0035, as compared with the corresponding
control values by one-way ANOVA followed by the Bonferroni modification of the t test for multiple comparisons).
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IaI is a known HA binding protein
(27). We show that the BALF concentration
of HA and IaI increased concomitantly in
the BALF of patients with CF (Figure 1C),
suggesting that these two extracellular
matrix components may be bound to each
other. Luminal HA is bound on the apical
surface of bronchial epithelia (41) and may
thus be the linking molecule that brings IaI
in apposition to the cell membrane.
Bikunin inhibits its protease substrates on
the cell surface much more efficiently than
in solution (42). Because ENaC activation
requires membrane-bound serine proteases,
IaI may be able to regulate ENaC activity
via increased concentration and proximity
to the cell surface. IaI is expressed by lung
epithelia as well (16), where it promotes
epithelial repair after injury. Thus, IaI may
also contribute to homeostatic ENaC
regulation in health and disease.
There is considerable controversy
whether increased ENaC activity
contributes to the pathophysiology of CF
disease (31, 43). Although it is known that
CF results from a defect in CFTR, a cAMP-
activated Cl2 channel, increased Na1
reabsorption in the airways of patients with
CF leading to decreased mucous hydration,
stasis, and increased susceptibility to
infections has been demonstrated (44, 45).
Furthermore, mice overexpressing
b-ENaCs develop CF-like symptoms with
mucus plugging (46). Our previous studies
in ΔF508, CFTR(1/2), and CFTR(2/2) mice
have shown an inverse correlation between
putative levels of CFTR and ENaC activity
in ATII cells (17). Another study reported
that increased functional CFTR decreases
ENaC activity by raising intracellular Cl2
(47). However, studies in newborn pigs
with CF disease found no evidence for
increased Na1 reabsorption across airway
epithelia (48, 49). Herein we report that
ΔF508 mice have significantly more
negative amiloride-sensitive NPD values
(223 vs.27 mV for wild-type mice), which
is in agreement with previous reports in
mice (50) and humans with CF (51). A
single intranasal instillation of IaI
decreased NPD by approximately 25% for
24 hours.
Previously, we reported that a1-
antitrypsin (a member of the SERPIN
Figure 6. IaI decreases ENaC activity of lung epithelial cells from wild-type (Wt) and CFTR-deficient mice in vitro and in situ. (A) Lung slices from Wt
(Control), ΔF508 (ΔF), and CFTR(2/2) mice were incubated with vehicle (V) or IaI (0.1 mg/ml) for 4 hours. Open probability (Po) for the 4- pS channel. Values
are means 6 SE (n = 20 patches per group; *,#P , 0.001) compared with the corresponding value to the immediate right and the control (Wt) value,
respectively; one-way ANOVA followed the Bonferroni modification of the t test adjusted for multiple comparisons. (B, C) Measurements of airway surface
liquid volume on murine nasal epithelial cells after addition of IaI (0.1 mg/ml) or vehicle (PBS) for 4 hours. (B) Confocal microscopy figures with the
cells labeled with Cell Tracker Green CMFDA and the apical surface fluid with Texas Red (further details are provided in the online supplement). Notice
the significant increase of the apical surface liquid on monolayers treated with IaI. Mean values 6 1 SE are shown in C. For comparison, some
monolayers were treated with amiloride (10 mM), which completely inhibits ENaC. Number of monolayers used were vehicle (control) = 11; IaI = 11;
amiloride = 14 (*P , 0.05 compared with Veh.; ANOVA (P = 0.001) followed by the Bonferroni modification of the t test for multiple comparisons). (D)
Measurements of the amiloride-sensitive component of nasal potential difference (NPD) in Wt and ΔF508 mice 4 or 24 hours after intranasal instillation of
IaI (0.1 mg/ml; 25 ml in each nostril). Values are means6 1 SE; number of mice are as follows: Wt (vehicle = 10); Wt IaI = 10; ΔF508 = 20 for each group. Statistical
significance is indicated in the graph and was determined as described above.
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family that lacks the Kunitz-type domain)
down-regulates both amiloride-sensitive
currents in vitro and Na1-dependent
alveolar fluid clearance across the distal
lung epithelia of anesthetized mice in vivo
(28). Protease inhibitor nexin 1, another
member of the SERPIN family that inhibits
matriptase (52, 53), also inhibited Na1
currents across human airway epithelial
cells isolated from CF lungs (52). Based on
Western blotting studies of surface proteins
of ATII cells in culture and in situ, we
conclude that IaI decreased ENaC activity
by preventing membran- bound proteases
from cleaving portions of the extracellular
loops of a- and g-ENaC subunits, thereby
inhibiting the activation of ENaC at the cell
membrane of lung epithelial cells and
oocytes. To the best of our knowledge, this
is the first demonstration of IaI inhibiting
membrane proteases involved in the
activation of ENaC at the surface of
epithelial cells in vitro, in situ, and in vivo
and involving oocytes expressing ENaC.
Our data show that IaI did not alter
CFTR activity because it does not require
proteolytic cleavage for its activation as
ENaCs do. The specific target proteases of
IaI have not been identified. Prostasin,
trypsin, and matriptase are possible targets
because they have been shown to activate
Na1 currents across human airway
epithelial cells isolated from CF lungs
(6, 32, 52, 53). Prostasin is synthesized as
an inactive zymogen that requires a site-
specific endoproteolytic cleavage to be
converted to an active protease. It has been
recently reported that matriptase is
necessary for prostasin activation (54).
Protease inhibitor nexin-1, like A1AT,
inhibits matriptase, which inactivates
ENaCs (52, 53). Another important
protease involved in ENaC activation is
furin (55). In fact, IaI has been shown to
inhibit furin activation of anthrax lethal
toxin and to protect animals from anthrax
intoxication (56). Furin is mainly found
intracellularly and cleaves ENaC during
trafficking to the cell surface (55).
However, furin-like activity has been
shown at the cell surface as well (57),
suggesting that extracellular IaI may
inhibit furin activity without having to
enter the cytoplasm.
There is significant evidence to show
that there is a large increase of protease to
antiprotease balance in the lungs of patients
with CF. There is excess secretion of serine
proteases (such as elastase, by activated
neutrophils), cysteine proteases (by alveolar
macrophages), matrix metalloproteinases
(airway cells), and bacterial proteases (by
P. aeruginosa). Unless deactivated by
antiproteases, these proteases increase lung
inflammation, degrade structural proteins,
and activate ENaCs, leading to
compromised respiratory function (58). For
this reason, administration of a-antitrypsin
to patients with CF has been shown to
decrease inflammation (59). However, the
antiprotease activity of a-antitrypsin may
be abrogated by oxidation of methionine
in its active site by a number of oxidants
(60), including peroxynitrite (28), the
concentration of which is known to
increase in the lungs of patients with
acute lung injury and CF (61, 62).
Whether or not IaI is subject to oxidative
posttranslational modifications has not
been determined. The overall increase of
antiprotease balance will benefit the lungs
by decreasing inflammation and ENaC
activity. Very little IaI was present in the
lung lavage fluid of ΔF508 mice, which is in
sharp contrast to the large amounts of IaI
and HA seen in the BALF of patients with
CF and in patients with lower airway
disease. This is consistent with the lack of
pulmonary disease in ΔF508 mice and with
the absence of lung inflammation in these
animals. It is possible that the presence of
significant amounts of IaI in patients will
down-regulate increased levels of airway
ENaCs, thus limiting mucous stasis, airway
obstruction, and compromised pulmonary
function. n
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